FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893683004> ?p ?o ?g. }

• W2893683004 abstract "INTRODUCTION Recurrence after primary treatment of cancer is one of the major challenges facing urologists. Biochemical recurrence is not rare and occurs in up to one third of the patients undergoing radical prostatectomy. Management of biochemical recurrence is tailored according to the site and the burden of recurrence. Therefore, developing an imaging technique to early detect recurrent lesions represents an urgent need. Positron emission tomography (PET) of 68Ga-labelled membrane antigen (68Ga-PSMA) is an emerging imaging modality that seems to be a promising tool with capability to localize recurrent cancer. A systematic review of literature was done to evaluate the role of 68Ga-PSMA PET/CT scan in patients with recurrent cancer after primary radical treatment. EVIDENCE ACQUISITION A systematic and comprehensive review of literature was performed in September 2017 analyzing the MEDLINE and Cochrane Library following the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. The following key terms were used for the search PSMA, prostate-specific membrane antigen, positron emission tomography, PET, recurrent, prostate cancer, prostate neoplasm, prostate malignancy, and 68Ga. Risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 tool. EVIDENCE SYNTHESIS Thirty-seven articles met our inclusion criteria and were included in the analysis of this systematic review. Of the 37 articles selected for analysis only four studies were prospective. The overall detection rate of 68Ga-PSMA PET scan ranged from 47% up to 96.6%. The main advantage of this imaging technique is its relatively high detection rates at low serum PSA levels below 0.5 ng/mL (ranging from 11.1% to 75%). Higher serum PSA level was strongly associated with increased positivity on 68Ga-PSMA PET scan. 68Ga-PSMA PET scan was found superior to conventional imaging techniques (CT and MRI) in this setting of patients and even it seems to outperform choline-based PET scan. This technique provided significant changes in the therapeutic management of 28.6-87.1% of patients. CONCLUSIONS After biochemical recurrence, the primary goal is to locate the recurrent lesions' site. 68Ga-PSMA PET/CT seems to be effective in identifying recurrence localization also for very low levels of PSA (<0.5 ng/mL) thus permitting to choose the best therapeutic strategy as early as possible. However, data available cannot be considered exhaustive and prospective randomized trials are needed." @default.
• W2893683004 created "2018-10-05" @default.
• W2893683004 creator A5008620361 @default.
• W2893683004 creator A5025120480 @default.
• W2893683004 creator A5028710627 @default.
• W2893683004 creator A5029284196 @default.
• W2893683004 creator A5032400726 @default.
• W2893683004 creator A5037237635 @default.
• W2893683004 creator A5048551247 @default.
• W2893683004 creator A5051421717 @default.
• W2893683004 creator A5058365243 @default.
• W2893683004 creator A5070495636 @default.
• W2893683004 creator A5082997583 @default.
• W2893683004 creator A5083745890 @default.
• W2893683004 creator A5089205145 @default.
• W2893683004 date "2018-09-01" @default.
• W2893683004 modified "2023-10-16" @default.
• W2893683004 title "The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature" @default.
• W2893683004 cites W1517749817 @default.
• W2893683004 cites W1900676315 @default.
• W2893683004 cites W1903999661 @default.
• W2893683004 cites W1973942000 @default.
• W2893683004 cites W2014999922 @default.
• W2893683004 cites W2021411036 @default.
• W2893683004 cites W2022099031 @default.
• W2893683004 cites W2071879495 @default.
• W2893683004 cites W2080006760 @default.
• W2893683004 cites W2091083791 @default.
• W2893683004 cites W2107638293 @default.
• W2893683004 cites W2120873855 @default.
• W2893683004 cites W2123161437 @default.
• W2893683004 cites W2134833483 @default.
• W2893683004 cites W2137670219 @default.
• W2893683004 cites W2211198407 @default.
• W2893683004 cites W2234163738 @default.
• W2893683004 cites W2235994423 @default.
• W2893683004 cites W2298184988 @default.
• W2893683004 cites W2299477037 @default.
• W2893683004 cites W2325838250 @default.
• W2893683004 cites W2410896679 @default.
• W2893683004 cites W2410901634 @default.
• W2893683004 cites W2412413888 @default.
• W2893683004 cites W2416073795 @default.
• W2893683004 cites W2463848034 @default.
• W2893683004 cites W2470255787 @default.
• W2893683004 cites W2504111721 @default.
• W2893683004 cites W2521395094 @default.
• W2893683004 cites W2540348172 @default.
• W2893683004 cites W2553708763 @default.
• W2893683004 cites W2556959447 @default.
• W2893683004 cites W2558756811 @default.
• W2893683004 cites W2561039633 @default.
• W2893683004 cites W2561605947 @default.
• W2893683004 cites W2567705791 @default.
• W2893683004 cites W2580998165 @default.
• W2893683004 cites W2588873924 @default.
• W2893683004 cites W2591970452 @default.
• W2893683004 cites W2598457068 @default.
• W2893683004 cites W2610570185 @default.
• W2893683004 cites W2612014481 @default.
• W2893683004 cites W2614800517 @default.
• W2893683004 cites W2615655377 @default.
• W2893683004 cites W2623906261 @default.
• W2893683004 cites W2642623263 @default.
• W2893683004 cites W2689197956 @default.
• W2893683004 cites W2736737591 @default.
• W2893683004 cites W2737584987 @default.
• W2893683004 cites W2744827740 @default.
• W2893683004 cites W286096609 @default.
• W2893683004 doi "https://doi.org/10.23736/s0393-2249.18.03081-3" @default.
• W2893683004 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29664244" @default.
• W2893683004 hasPublicationYear "2018" @default.
• W2893683004 type Work @default.
• W2893683004 sameAs 2893683004 @default.
• W2893683004 citedByCount "58" @default.
• W2893683004 countsByYear W28936830042018 @default.
• W2893683004 countsByYear W28936830042019 @default.
• W2893683004 countsByYear W28936830042020 @default.
• W2893683004 countsByYear W28936830042021 @default.
• W2893683004 countsByYear W28936830042022 @default.
• W2893683004 countsByYear W28936830042023 @default.
• W2893683004 crossrefType "journal-article" @default.
• W2893683004 hasAuthorship W2893683004A5008620361 @default.
• W2893683004 hasAuthorship W2893683004A5025120480 @default.
• W2893683004 hasAuthorship W2893683004A5028710627 @default.
• W2893683004 hasAuthorship W2893683004A5029284196 @default.
• W2893683004 hasAuthorship W2893683004A5032400726 @default.
• W2893683004 hasAuthorship W2893683004A5037237635 @default.
• W2893683004 hasAuthorship W2893683004A5048551247 @default.
• W2893683004 hasAuthorship W2893683004A5051421717 @default.
• W2893683004 hasAuthorship W2893683004A5058365243 @default.
• W2893683004 hasAuthorship W2893683004A5070495636 @default.
• W2893683004 hasAuthorship W2893683004A5082997583 @default.
• W2893683004 hasAuthorship W2893683004A5083745890 @default.
• W2893683004 hasAuthorship W2893683004A5089205145 @default.
• W2893683004 hasConcept C121608353 @default.
• W2893683004 hasConcept C126322002 @default.
• W2893683004 hasConcept C126838900 @default.
• W2893683004 hasConcept C143998085 @default.
• W2893683004 hasConcept C2777008409 @default.

• next